CM
VIR icon

Capula Management’s Vir Biotechnology VIR Stock Holding History

Capula Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-32,334
Closed -$210K – 856
2025
Q1 		$210K Buy
+32,334
New +$287K ﹤0.01% 514
2024
Q2 		– Sell
-92,153
Closed -$934K – 672
2024
Q1 		$934K Buy
+92,153
New +$939K 0.02% 103
2023
Q1 		– Sell
-36,050
Closed -$912K – 939
2022
Q4 		$912K Buy
+36,050
New +$884K 0.01% 466

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capula Management's VIR Position: Q2 2025 in Review

Capula Management sold out of Vir Biotechnology (VIR) in Q2 2025, closing a stake of 32,334 shares — an estimated $210K sold.

Capula Management first reported a position in VIR in Q4 2022 and held it in 3 quarters. The position peaked at $934K in Q1 2024. 213 funds tracked by Wall St. Rank hold VIR as of Q2 2025.

  • Capula Management reported no remaining Vir Biotechnology position as of Q2 2025 after selling out during the quarter.
  • Capula Management sold 32,334 Vir Biotechnology shares in Q2 2025, an estimated $210K.
  • Capula Management first reported a position in Vir Biotechnology in Q4 2022 and held it in 3 quarters.
  • Capula Management's Vir Biotechnology position peaked at $934K in Q1 2024.
  • 213 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2025.

Based on Capula Management's 13F filing for Q2 2025, filed 13 Aug 2025.